HaluGen Life Sciences Inc.
The test will serve as a pre-screening platform for patients looking into psychedelics-assisted psychotherapy, giving out “genetic, personal and familial insights” to improve patient care and reduce possible risks associated with the therapy. For Entheon, the launch of this product also represents our first revenue stream as we work to develop commercial partnerships for the mass sale of the test,” said CEO Timothy Ko.
The company said the test is now available for sale in Canada, and expects to offer availability in the U.S. in coming months.
How Does It Work?
The technology, which has existed in similar variants in the cannabis industry for a few years, is a psychedelics first, according to the company.
Entheon Biomedical Corp. Launches HaluGen s Psychedelics Genetic Test
HaluGen s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy
Vancouver, British Columbia (Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ( Entheon or the Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ( HaluGen ), and that it is now available for sale within Canada.
HaluGen s psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one s psychedelic assisted therapy experience. By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic assisted therapy patient care and reduce side effects and risk. Th
Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule.
(2)
Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon s Advisory Board
Vancouver, British Columbia (Newsfile Corp. - March 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company s data strategy design, study design and advise on regulatory relationships and data strategy.
Ms. Maher has served as an executive and consultant for major pharmaceutical and information technology companies, including IBM, Gilead, Schering-Plough, Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is currently SVP, Chief Information Officer, North America of Kyo
Psychedelic Summit Talks Legalization Prep cannabisculture.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cannabisculture.com Daily Mail and Mail on Sunday newspapers.